Everett E. Vokes to Head and Neck Neoplasms
This is a "connection" page, showing publications Everett E. Vokes has written about Head and Neck Neoplasms.
Connection Strength
16.207
-
Phase I study of nab-paclitaxel-based induction followed by nab-paclitaxel-based concurrent chemotherapy and re-irradiation in previously treated head and neck squamous cell carcinoma. Br J Cancer. 2022 11; 127(8):1497-1506.
Score: 0.513
-
Is This the Dawn of Precision Oncology in Head and Neck Cancer? J Clin Oncol. 2021 06 10; 39(17):1839-1841.
Score: 0.469
-
Optimizing Treatment De-Escalation in Head and Neck Cancer: Current and Future Perspectives. Oncologist. 2021 01; 26(1):40-48.
Score: 0.451
-
A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO study. Cancer. 2020 07 15; 126(14):3237-3243.
Score: 0.439
-
Prolonging Life, but at What Price? JAMA Otolaryngol Head Neck Surg. 2019 12 01; 145(12):1103-1104.
Score: 0.426
-
Epidermal Growth Factor Receptor Blockade in Head and Neck Cancer: What Remains? J Clin Oncol. 2019 11 01; 37(31):2807-2814.
Score: 0.419
-
Palbociclib: a new partner for cetuximab? Lancet Oncol. 2019 09; 20(9):1195-1196.
Score: 0.416
-
Management of Early Head and Neck Cancer in Elderly Patients. J Oncol Pract. 2018 09; 14(9):541-546.
Score: 0.391
-
Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 2016 09 01; 96(1):21-9.
Score: 0.333
-
HPV-Associated Head and Neck Cancer. J Natl Cancer Inst. 2015 Dec; 107(12):djv344.
Score: 0.323
-
Reply to s. Chakraborty et al. J Clin Oncol. 2015 Mar 10; 33(8):968.
Score: 0.305
-
EGFR-based bioradiotherapy in SCCHN. Lancet Oncol. 2015 Feb; 16(2):129-30.
Score: 0.304
-
Comparison of outcomes of locoregionally advanced oropharyngeal and non-oropharyngeal squamous cell carcinoma over two decades. Ann Oncol. 2015 Jan; 26(1):198-205.
Score: 0.299
-
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol. 2014 Sep 01; 32(25):2735-43.
Score: 0.294
-
DNA repair biomarkers XPF and phospho-MAPKAP kinase 2 correlate with clinical outcome in advanced head and neck cancer. PLoS One. 2014; 9(7):e102112.
Score: 0.293
-
EGFR-directed treatments in SCCHN. Lancet Oncol. 2013 Jul; 14(8):672-3.
Score: 0.272
-
A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFeradeā¢ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation. Ann Oncol. 2013 Mar; 24(3):769-76.
Score: 0.261
-
A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers. Ann Oncol. 2011 Oct; 22(10):2304-9.
Score: 0.232
-
Head and neck cancer in 2010: Maximizing survival and minimizing toxicity. Nat Rev Clin Oncol. 2011 Feb; 8(2):72-4.
Score: 0.231
-
Radiotherapy: Accelerated radiotherapy for HNSCC in developing countries. Nat Rev Clin Oncol. 2010 Nov; 7(11):616-8.
Score: 0.227
-
Adjuvant chemotherapy prior to postoperative concurrent chemoradiotherapy for locoregionally advanced head and neck cancer. Radiother Oncol. 2010 Nov; 97(2):318-21.
Score: 0.226
-
Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol. 2010 Jul 10; 28(20):3336-43.
Score: 0.220
-
Induction chemotherapy for head and neck cancer: recent data. Oncologist. 2010; 15 Suppl 3:3-7.
Score: 0.214
-
Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2009 Oct; 45(10):e155-60.
Score: 0.207
-
Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol. 2009 Apr 10; 27(11):1864-71.
Score: 0.203
-
Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol. 2009 Mar; 10(3):247-57.
Score: 0.201
-
Induction chemotherapy: to use or not to use? That is the question. Semin Radiat Oncol. 2009 Jan; 19(1):11-6.
Score: 0.200
-
Introduction: head and neck cancer. Semin Oncol. 2008 Jun; 35(3):196-7.
Score: 0.192
-
Concurrent chemotherapy and re-irradiation for locoregionally recurrent head and neck cancer. Semin Oncol. 2008 Jun; 35(3):251-61.
Score: 0.192
-
Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J Clin Oncol. 2008 Apr 01; 26(10):1732-41.
Score: 0.190
-
Combining radiotherapy with systemic therapies. Clin Adv Hematol Oncol. 2008 Mar; 6(3):167-9.
Score: 0.189
-
Expanding role of the medical oncologist in the management of head and neck cancer. CA Cancer J Clin. 2008 Jan-Feb; 58(1):32-53.
Score: 0.186
-
Chemoradiotherapy for locally advanced head and neck cancer. J Clin Oncol. 2007 Sep 10; 25(26):4118-26.
Score: 0.183
-
A phase I trial of docetaxel based induction and concomitant chemotherapy in patients with locally advanced head and neck cancer. Cancer Invest. 2007 Sep; 25(6):435-44.
Score: 0.182
-
The chemoradiation paradigm in head and neck cancer. Nat Clin Pract Oncol. 2007 Mar; 4(3):156-71.
Score: 0.176
-
High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial. J Clin Oncol. 2006 Jul 20; 24(21):3438-44.
Score: 0.169
-
A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer. Cancer Biol Ther. 2006 Jul; 5(7):766-70.
Score: 0.168
-
Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers. Oncology (Williston Park). 2006 Apr; 20(5 Suppl 2):15-25.
Score: 0.165
-
Planned post-chemoradiation neck dissection: significance of radiation dose. Laryngoscope. 2006 Jan; 116(1):33-6.
Score: 0.162
-
Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res. 2005 Dec 01; 11(23):8418-24.
Score: 0.161
-
Phase I study of concomitant chemoradiotherapy with irinotecan, 5-FU, and hydroxyurea for patients with advanced and/or recurrent head and neck cancer. Cancer J. 2005 Mar-Apr; 11(2):140-6.
Score: 0.153
-
Current treatments and promising investigations in a multidisciplinary setting. Ann Oncol. 2005; 16 Suppl 6:vi25-vi30.
Score: 0.152
-
Update in head and neck oncology. Semin Oncol. 2004 Dec; 31(6):717.
Score: 0.151
-
Concurrent chemoradiotherapy for head and neck cancer. Semin Oncol. 2004 Dec; 31(6):786-93.
Score: 0.151
-
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neck. Clin Cancer Res. 2004 Aug 01; 10(15):4922-32.
Score: 0.147
-
The expanding role of systemic therapy in head and neck cancer. J Clin Oncol. 2004 May 01; 22(9):1743-52.
Score: 0.145
-
Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer. Head Neck. 2004 May; 26(5):447-55.
Score: 0.145
-
Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy. Clin Cancer Res. 2004 Mar 15; 10(6):1956-62.
Score: 0.143
-
Prioritizing treatment outcomes: head and neck cancer patients versus nonpatients. Head Neck. 2004 Feb; 26(2):163-70.
Score: 0.142
-
Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer. Clin Cancer Res. 2003 Dec 01; 9(16 Pt 1):5936-43.
Score: 0.141
-
Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2003 May 15; 21(10):1980-7.
Score: 0.135
-
Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer. Clin Cancer Res. 2003 May; 9(5):1689-97.
Score: 0.135
-
Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol. 2003 Jan 15; 21(2):320-6.
Score: 0.132
-
Intensive concurrent chemoradiotherapy for head and neck cancer with 5-Fluorouracil- and hydroxyurea-based regimens: reversing a pattern of failure. Oncologist. 2003; 8(4):350-60.
Score: 0.132
-
A Randomized Multi-institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck. Clin Cancer Res. 2022 12 01; 28(23):5040-5048.
Score: 0.131
-
An exploration of the pretreatment coping strategies of patients with carcinoma of the head and neck. Cancer. 2002 Jul 01; 95(1):98-104.
Score: 0.127
-
Curative treatment for advanced head and neck cancer in the community: has the time come? Cancer J. 2002 Jul-Aug; 8(4):298-300.
Score: 0.127
-
Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141. Oncologist. 2022 03 04; 27(2):e194-e198.
Score: 0.125
-
Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis. Lancet Oncol. 2021 05; 22(5):727-736.
Score: 0.117
-
Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. J Clin Oncol. 2000 Apr; 18(8):1652-61.
Score: 0.109
-
A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma. Cancer. 2020 05 15; 126(10):2146-2152.
Score: 0.108
-
A pilot study of the pan-class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent or metastatic head and neck cancer. Head Neck. 2019 11; 41(11):3842-3849.
Score: 0.105
-
Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial. Cancer. 2019 09 15; 125(18):3208-3218.
Score: 0.103
-
Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use. Clin Cancer Res. 2019 09 01; 25(17):5221-5230.
Score: 0.103
-
CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer. Oncologist. 2018 09; 23(9):1079-1082.
Score: 0.096
-
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. Lancet Oncol. 2017 08; 18(8):1104-1115.
Score: 0.090
-
Characterization of the T-Cell Receptor Repertoire and Immune Microenvironment in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2017 Aug 15; 23(16):4897-4907.
Score: 0.089
-
Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma. Oncotarget. 2017 Mar 21; 8(12):18726-18734.
Score: 0.088
-
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016 11 10; 375(19):1856-1867.
Score: 0.086
-
Ex vivo antibody-dependent cellular cytotoxicity inducibility predicts efficacy of cetuximab. Cancer Immunol Res. 2015 May; 3(5):567-74.
Score: 0.077
-
Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes. Clin Cancer Res. 2015 Feb 15; 21(4):870-81.
Score: 0.075
-
Rare occurrence of EGFRvIII deletion in head and neck squamous cell carcinoma. Oral Oncol. 2015 Jan; 51(1):53-8.
Score: 0.074
-
Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin Cancer Res. 2015 Feb 01; 21(3):632-41.
Score: 0.073
-
Poly (ADP-ribose) polymerase inhibitor efficacy in head and neck cancer. Oral Oncol. 2014 Sep; 50(9):825-31.
Score: 0.073
-
Race and competing mortality in advanced head and neck cancer. Oral Oncol. 2014 Jan; 50(1):40-4.
Score: 0.070
-
Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2012 Sep; 48(9):887-92.
Score: 0.063
-
A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res. 2012 Apr 15; 18(8):2336-43.
Score: 0.062
-
Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation. Cancer. 2011 Oct 15; 117(20):4671-8.
Score: 0.059
-
Phase II trial of pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated patients with squamous cell carcinoma of the head and neck. Ann Oncol. 2011 Nov; 22(11):2501-2507.
Score: 0.058
-
Germline polymorphisms discovered via a cell-based, genome-wide approach predict platinum response in head and neck cancers. Transl Res. 2011 May; 157(5):265-72.
Score: 0.058
-
Factors associated with long-term speech and swallowing outcomes after chemoradiotherapy for locoregionally advanced head and neck cancer. Arch Otolaryngol Head Neck Surg. 2010 Dec; 136(12):1226-34.
Score: 0.057
-
Predictors of competing mortality in advanced head and neck cancer. J Clin Oncol. 2010 Jan 01; 28(1):15-20.
Score: 0.053
-
Neck response to chemoradiotherapy: complete radiographic response correlates with pathologic complete response in locoregionally advanced head and neck cancer. Arch Otolaryngol Head Neck Surg. 2009 Nov; 135(11):1133-6.
Score: 0.053
-
Neck dissection planning based on postchemoradiation computed tomography in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2009 Sep; 135(9):876-80.
Score: 0.052
-
Phase II study of sunitinib malate in head and neck squamous cell carcinoma. Invest New Drugs. 2010 Oct; 28(5):677-83.
Score: 0.052
-
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009 Apr 01; 69(7):3021-31.
Score: 0.051
-
Characteristics associated with swallowing changes after concurrent chemotherapy and radiotherapy in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2008 Oct; 134(10):1060-5.
Score: 0.049
-
Free-flap reconstruction in the doubly irradiated patient population. Plast Reconstr Surg. 2008 Jul; 122(1):125-132.
Score: 0.048
-
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol. 2008 Mar 01; 26(7):1119-27.
Score: 0.047
-
Aspiration in chemoradiated patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2007 Dec; 133(12):1289-95.
Score: 0.046
-
A randomized validation study comparing embedded versus extracted FACT Head and Neck Symptom Index scores. Qual Life Res. 2007 Dec; 16(10):1615-26.
Score: 0.046
-
Phase I trial of tirapazamine, cisplatin, and concurrent accelerated boost reirradiation in patients with recurrent head and neck cancer. Int J Radiat Oncol Biol Phys. 2007 Mar 01; 67(3):678-84.
Score: 0.044
-
The 2007 Inaugural ASTRO/ASCO/AHNS Multidisciplinary Head and Neck Cancer Symposium. Int J Radiat Oncol Biol Phys. 2007; 69(2 Suppl):S1-3.
Score: 0.044
-
Pilot study examining tumor expression of RAD51 and clinical outcomes in human head cancers. Int J Oncol. 2006 May; 28(5):1113-9.
Score: 0.042
-
Intensity-modulated radiation therapy in advanced head and neck patients treated with intensive chemoradiotherapy: preliminary experience and future directions. Int J Oncol. 2006 May; 28(5):1141-51.
Score: 0.042
-
Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst. 2006 Apr 05; 98(7):441-50.
Score: 0.041
-
Site of disease and treatment protocol as correlates of swallowing function in patients with head and neck cancer treated with chemoradiation. Head Neck. 2006 Jan; 28(1):64-73.
Score: 0.041
-
Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin Cancer Res. 2005 Nov 15; 11(22):8105-8.
Score: 0.040
-
Somatic acquisition and signaling of TGFBR1*6A in cancer. JAMA. 2005 Oct 05; 294(13):1634-46.
Score: 0.040
-
Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2006 Feb 01; 64(2):382-91.
Score: 0.040
-
Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol. 2005 Aug 20; 23(24):5578-87.
Score: 0.039
-
Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy. Int J Radiat Oncol Biol Phys. 2005 Mar 15; 61(4):1096-106.
Score: 0.038
-
Cetuximab in cancers of the lung and head & neck. Semin Oncol. 2004 Feb; 31(1 Suppl 1):61-7.
Score: 0.036
-
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol. 2004 Jan 01; 22(1):77-85.
Score: 0.035
-
Swallowing dysfunction--preventative and rehabilitation strategies in patients with head-and-neck cancers treated with surgery, radiotherapy, and chemotherapy: a critical review. Int J Radiat Oncol Biol Phys. 2003 Dec 01; 57(5):1219-30.
Score: 0.035
-
Is patient travel distance associated with survival on phase II clinical trials in oncology? J Natl Cancer Inst. 2003 Sep 17; 95(18):1370-5.
Score: 0.035
-
Efficacy of the multi-kinase inhibitor enzastaurin is dependent on cellular signaling context. Mol Cancer Ther. 2010 Oct; 9(10):2814-24.
Score: 0.014
-
Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol. 2006 Jan 01; 24(1):190-205.
Score: 0.010